Biomarkers of METAP2 inhibitors and applications thereof
US12419846B2 · kind B2 · utility
0Cited by
27References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2023 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Jun 23, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, metabolic dysfunction associated with a treatment in a subject having cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.